NCT05032833
ClinicalTrials.gov
- Trial ID
- T-ctgov-NCT05032833
- Registry
- ClinicalTrials.gov
- NCT number
- NCT05032833
- Asset
- BPL-003
- Sponsor, as registered
- Beckley Psytech Limited
- Phase
- PHASE1
- Indication
- Pharmacokinetics in Healthy Adults
- Status
- COMPLETED
- Start date
- 2021-09-22
- Primary completion
- 2022-07-07
- Registered countries
- United Kingdom
- Sites
- 1
The sponsor's registered location list, which states intent rather than approval.
clinicaltrials.govctgov registryverified 2026-10-13inferred
Notes on the record
New row; supersedes nothing (no prior row for this trial_id). Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country. Read 2026-10-13 Berlin; lastUpdatePostDate 2022-10-12. Org study id BPL-5MEO-101; official title: first-in-human single ascending dose study of intranasal 5-MeO-DMT; intervention named '5-MeO-DMT', administered intranasally. asset_id A001-bpl-003 is INFERRED from sponsor, route and study id: the record never names BPL-003. Added for Issue 18, which cites it among BPL-003 records (preflight).
Company
Through BPL-003: Beckley Psytech and AtaiBeckley
Cited in
Issues quoting NCT05032833 in their own text.